Optimization and efficacy study of synergistic vincristine coloaded liposomal doxorubicin against breast and lung cancer
Aim: To improve the efficacy of poly-ethylene glycol (PEG)ylated liposomes coloaded with doxorubicin and vincristine against triple-negative breast cancer (TNBC) and non-small-cell lung cancer (NSCLC). Methods: The combinatorial index of the drugs was established using the Chou-Talalay method in MDA-MB-231 and A549 cell lines. The most effective ratio was co-encapsulated in factorial design optimized nanoliposomes which were characterized for similarity to clinical standard and evaluated in vitro and in vivo for therapeutic efficacy. Results & conclusion: The formulation exhibited more than 95% co-encapsulation, a size of 95.74 ± 2.65 nm and zeta potential of -9.17 ± 1.19 mV while having no significant differences in physicochemical and biochemical characteristics as compared with the clinical standard. Efficacy evaluation studies showed significantly improved cytotoxicity and tumor regression compared with liposomal doxorubicin indicating improvement in efficacy against TNBC and NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 15(2020), 26 vom: 22. Nov., Seite 2585-2607 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghosh, Saikat [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.07.2021 Date Revised 28.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2020-0169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316590290 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316590290 | ||
| 003 | DE-627 | ||
| 005 | 20231225161422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2020-0169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316590290 | ||
| 035 | |a (NLM)33090073 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghosh, Saikat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimization and efficacy study of synergistic vincristine coloaded liposomal doxorubicin against breast and lung cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2021 | ||
| 500 | |a Date Revised 28.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To improve the efficacy of poly-ethylene glycol (PEG)ylated liposomes coloaded with doxorubicin and vincristine against triple-negative breast cancer (TNBC) and non-small-cell lung cancer (NSCLC). Methods: The combinatorial index of the drugs was established using the Chou-Talalay method in MDA-MB-231 and A549 cell lines. The most effective ratio was co-encapsulated in factorial design optimized nanoliposomes which were characterized for similarity to clinical standard and evaluated in vitro and in vivo for therapeutic efficacy. Results & conclusion: The formulation exhibited more than 95% co-encapsulation, a size of 95.74 ± 2.65 nm and zeta potential of -9.17 ± 1.19 mV while having no significant differences in physicochemical and biochemical characteristics as compared with the clinical standard. Efficacy evaluation studies showed significantly improved cytotoxicity and tumor regression compared with liposomal doxorubicin indicating improvement in efficacy against TNBC and NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chou-Talalay method | |
| 650 | 4 | |a PEGylated | |
| 650 | 4 | |a combination | |
| 650 | 4 | |a doxorubicin | |
| 650 | 4 | |a factorial design | |
| 650 | 4 | |a liposome | |
| 650 | 4 | |a non-small-cell lung cancer | |
| 650 | 4 | |a synergism | |
| 650 | 4 | |a triple-negative breast cancer | |
| 650 | 4 | |a vincristine | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a liposomal doxorubicin |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Vincristine |2 NLM | |
| 650 | 7 | |a 5J49Q6B70F |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 700 | 1 | |a Lalani, Rohan |e verfasserin |4 aut | |
| 700 | 1 | |a Maiti, Kuntal |e verfasserin |4 aut | |
| 700 | 1 | |a Banerjee, Shubhadeep |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Bhowmick, Subhas |e verfasserin |4 aut | |
| 700 | 1 | |a Misra, Ambikanandan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 15(2020), 26 vom: 22. Nov., Seite 2585-2607 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2020 |g number:26 |g day:22 |g month:11 |g pages:2585-2607 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2020-0169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2020 |e 26 |b 22 |c 11 |h 2585-2607 | ||